Difference between revisions of "Part:BBa K3142005:Design"
(→References) |
|||
| (2 intermediate revisions by the same user not shown) | |||
| Line 7: | Line 7: | ||
===Design Notes=== | ===Design Notes=== | ||
| − | + | The sequence has been optimized for lactic acid bacteria. It is a small molecule bioactive peptide that is difficult to directly biosynthesize. Therefore, the fusion expression strategy is currently used. | |
| − | + | ||
| − | + | ||
===Source=== | ===Source=== | ||
| Line 16: | Line 14: | ||
===References=== | ===References=== | ||
| + | |||
| + | Martin, M, A. Wellner, I. Ossowski, and T. Henle. Identification and quantification of inhibitors for Angiotensin-converting enzyme in hypoallergenic infant milk formulas.[J] Agric Food Chem. 2006,56:6333–6338. | ||
Latest revision as of 22:09, 20 October 2019
Antihypertensive dipeptide（VY）
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]
Design Notes
The sequence has been optimized for lactic acid bacteria. It is a small molecule bioactive peptide that is difficult to directly biosynthesize. Therefore, the fusion expression strategy is currently used.
Source
no
References
Martin, M, A. Wellner, I. Ossowski, and T. Henle. Identification and quantification of inhibitors for Angiotensin-converting enzyme in hypoallergenic infant milk formulas.[J] Agric Food Chem. 2006,56:6333–6338.